Bernard Vanhove holds a PhD in immunological sciences (University of Louvain, Belgium).
He started an international scientific career at the Sandoz Vienna International Research Cooperation Center, Vienna, Austria and then spent 20 years at the INSERM/University of Nantes, France.
CNRS Research Director, he developed novel immunotherapies in transplantation, autoimmunity and immuno-oncology.
He authored a hundred peer-reviewed scientific publications and applied for > 20 patents.
In 2008, Bernard Vanhove co-founded Effimune and served as Chief Executive Officer, then became Chief Operating Officer of OSE Immunotherapeutics, where he contributed to introduce 3 biotherapeutics issued from his research team into clinical development.
In 2019, he joined Xenothera as Chief Scientific and Operating Officer.